Recognizing that developmental research funds are an integral part of the SPORE, we commit $75,000 per year to these endeavors. In addition, matching funds of $50,000/year are committed to this program from the University of Michigan Medical School. This represents a significant percent of the budget of the UMCC Head and Neck SPORE and reflects the continued commitment of this program to the development of innovative translational research in head and neck cancer. The focus of the Developmental Research Program is to provide investigators the ability to generate data that will become the preliminary data for an R01 grant application of an equivalent proposal. Investigators from outside the field of head and neck cancer are encouraged to apply through campus-wide announcements as well as through personal interactions with SPORE investigators. A stepwise proposal solicitation and review process has been developed utilizing NIH-type PHS 398 format applications that have been streamlined for rapid turn around of research proposals and which recognizes that these projects may have little preliminary data. Investigators may apply for support in the amount of $50,000 for a one- or two-year funding period. Since 2002 we have funded 18 developmental projects, representing a total investment of $790,000;This has resulted in over $2.6 million (direct costs) in subsequent grants, 13 manuscripts, and 4 abstracts. Dr. Gregory Wolf and Dr. Thomas Carey serve as Directors for the Developmental Research Program. Both are leaders in head and neck cancer, and hold institutional leadership positions. Together with the Senior Advisory Council, they are adept at selecting the highest quality proposals for funding and providing the necessary mentorship and support to guarantee success with this program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Wolf, Gregory T; Bellile, Emily; Eisbruch, Avraham et al. (2017) Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg 143:355-366
Getz, Kayla R; Rozek, Laura S; Peterson, Lisa A et al. (2017) Family history of cancer and head and neck cancer survival. Laryngoscope 127:1816-1820
Hoban, Connor W; Beesley, Lauren J; Bellile, Emily L et al. (2017) Individualized outcome prognostication for patients with laryngeal cancer. Cancer :
Kim, Hong Sun; Chen, Yu-Chih; Nör, Felipe et al. (2017) Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels. Oncotarget 8:100339-100352
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Kerk, Samuel A; Finkel, Kelsey A; Pearson, Alexander T et al. (2017) 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 23:2516-2527
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Udager, A M; McHugh, J B; Goudsmit, C M et al. (2017) Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. Ann Oncol :
Gainor, Danielle L; Marchiano, Emily; Bellile, Emily et al. (2017) Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. Otolaryngol Head Neck Surg 157:625-630
Nör, Felipe; Warner, Kristy A; Zhang, Zhaocheng et al. (2017) Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res 23:1036-1048

Showing the most recent 10 out of 249 publications